158 related articles for article (PubMed ID: 36336710)
21. Inhibition of microRNA-196a might reverse cisplatin resistance of A549/DDP non-small-cell lung cancer cell line.
Li JH; Luo N; Zhong MZ; Xiao ZQ; Wang JX; Yao XY; Peng Y; Cao J
Tumour Biol; 2016 Feb; 37(2):2387-94. PubMed ID: 26376998
[TBL] [Abstract][Full Text] [Related]
22. Ginsenoside Rd reverses cisplatin resistance in non-small-cell lung cancer A549 cells by downregulating the nuclear factor erythroid 2-related factor 2 pathway.
Chian S; Zhao Y; Xu M; Yu X; Ke X; Gao R; Yin L
Anticancer Drugs; 2019 Sep; 30(8):838-845. PubMed ID: 31415285
[TBL] [Abstract][Full Text] [Related]
23. Long noncoding LUCAT1 promotes cisplatin resistance of non-small cell lung cancer by promoting IGF-2.
Wang W; Dong ML; Zhang W; Liu T
Eur Rev Med Pharmacol Sci; 2019 Jun; 23(12):5229-5234. PubMed ID: 31298373
[TBL] [Abstract][Full Text] [Related]
24. Niclosamide enhances the cytotoxic effect of cisplatin in cisplatin-resistant human lung cancer cells via suppression of lung resistance-related protein and c-myc.
Zuo Y; Yang D; Yu Y; Xiang M; Li H; Yang J; Li J; Jiang D; Zhou H; Xu Z; Yu Z
Mol Med Rep; 2018 Mar; 17(3):3497-3502. PubMed ID: 29257330
[TBL] [Abstract][Full Text] [Related]
25. p32/OPA1 axis-mediated mitochondrial dynamics contributes to cisplatin resistance in non-small cell lung cancer.
Yu CX; Peng ZQ; Wang T; Qu XH; Yang P; Huang SR; Jiang LP; Tou FF; Han XJ
Acta Biochim Biophys Sin (Shanghai); 2024 Jan; 56(1):34-43. PubMed ID: 38151998
[TBL] [Abstract][Full Text] [Related]
26. Profiling of apoptosis- and autophagy-associated molecules in human lung cancer A549 cells in response to cisplatin treatment using stable isotope labeling with amino acids in cell culture.
Wang Z; Liu G; Jiang J
Int J Oncol; 2019 Mar; 54(3):1071-1085. PubMed ID: 30664195
[TBL] [Abstract][Full Text] [Related]
27. [SIRT1 Influences the Sensitivity of A549 Non-small Cell Lung Cancer Cell Line to
Cisplatin via Modulating the Noxa Expression].
Cao B; He X; Wang W; Shi M
Zhongguo Fei Ai Za Zhi; 2016 Feb; 19(2):57-63. PubMed ID: 26903157
[TBL] [Abstract][Full Text] [Related]
28. EHD1 confers resistance to cisplatin in non-small cell lung cancer by regulating intracellular cisplatin concentrations.
Gao J; Meng Q; Zhao Y; Chen X; Cai L
BMC Cancer; 2016 Jul; 16():470. PubMed ID: 27411790
[TBL] [Abstract][Full Text] [Related]
29. The PVT1/miR-216b/Beclin-1 regulates cisplatin sensitivity of NSCLC cells via modulating autophagy and apoptosis.
Chen L; Han X; Hu Z; Chen L
Cancer Chemother Pharmacol; 2019 May; 83(5):921-931. PubMed ID: 30859368
[TBL] [Abstract][Full Text] [Related]
30. Increased ABCC2 expression predicts cisplatin resistance in non-small cell lung cancer.
Chen Y; Zhou H; Yang S; Su D
Cell Biochem Funct; 2021 Mar; 39(2):277-286. PubMed ID: 32815556
[TBL] [Abstract][Full Text] [Related]
31. TRIM59 knockdown blocks cisplatin resistance in A549/DDP cells through regulating PTEN/AKT/HK2.
He R; Liu H
Gene; 2020 Jul; 747():144553. PubMed ID: 32165307
[TBL] [Abstract][Full Text] [Related]
32. Circ_PIP5K1A regulates cisplatin resistance and malignant progression in non-small cell lung cancer cells and xenograft murine model via depending on miR-493-5p/ROCK1 axis.
Feng N; Guo Z; Wu X; Tian Y; Li Y; Geng Y; Yu Y
Respir Res; 2021 Sep; 22(1):248. PubMed ID: 34537072
[TBL] [Abstract][Full Text] [Related]
33. Overexpression of miR-203 increases the sensitivity of NSCLC A549/H460 cell lines to cisplatin by targeting Dickkopf-1.
Cheng R; Lu C; Zhang G; Zhang G; Zhao G
Oncol Rep; 2017 Apr; 37(4):2129-2136. PubMed ID: 28350100
[TBL] [Abstract][Full Text] [Related]
34. XPC inhibition rescues cisplatin resistance via the Akt/mTOR signaling pathway in A549/DDP lung adenocarcinoma cells.
Teng X; Fan XF; Li Q; Liu S; Wu DY; Wang SY; Shi Y; Dong M
Oncol Rep; 2019 Mar; 41(3):1875-1882. PubMed ID: 30628719
[TBL] [Abstract][Full Text] [Related]
35. ELF1 activated long non-coding RNA CASC2 inhibits cisplatin resistance of non-small cell lung cancer via the miR-18a/IRF-2 signaling pathway.
Xiao XH; He SY
Eur Rev Med Pharmacol Sci; 2020 Mar; 24(6):3130-3142. PubMed ID: 32271431
[TBL] [Abstract][Full Text] [Related]
36. Elevation of FGD5-AS1 contributes to cell progression by improving cisplatin resistance against non-small cell lung cancer cells through regulating miR-140-5p/WEE1 axis.
Fu J; Cai H; Wu Y; Fang S; Wang D
Gene; 2020 Sep; 755():144886. PubMed ID: 32534055
[TBL] [Abstract][Full Text] [Related]
37. Hypermethylation of ATP-binding cassette B1 (ABCB1) multidrug resistance 1 (MDR1) is associated with cisplatin resistance in the A549 lung adenocarcinoma cell line.
Li A; Song J; Lai Q; Liu B; Wang H; Xu Y; Feng X; Sun X; Du Z
Int J Exp Pathol; 2016 Dec; 97(6):412-421. PubMed ID: 27995666
[TBL] [Abstract][Full Text] [Related]
38. GAS5 modulated autophagy is a mechanism modulating cisplatin sensitivity in NSCLC cells.
Zhang N; Yang GQ; Shao XM; Wei L
Eur Rev Med Pharmacol Sci; 2016 Jun; 20(11):2271-7. PubMed ID: 27338051
[TBL] [Abstract][Full Text] [Related]
39. CXCR4 promotes cisplatin-resistance of non-small cell lung cancer in a CYP1B1-dependent manner.
Xie S; Tu Z; Xiong J; Kang G; Zhao L; Hu W; Tan H; Tembo KM; Ding Q; Deng X; Huang J; Zhang Q
Oncol Rep; 2017 Feb; 37(2):921-928. PubMed ID: 27922681
[TBL] [Abstract][Full Text] [Related]
40. [Role of SOX4 on DDP Resistance in Non-small Cell Lung Cancer Cell of A549].
Li W; Liu X; Zhang G; Zhang L
Zhongguo Fei Ai Za Zhi; 2017 May; 20(5):298-302. PubMed ID: 28532536
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
